Drugs / BMS-986299
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03444753 | Apr 2018 → Feb 2022 | — | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986299 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03444753 ↗ |
| Modality | Small molecule | — CHEMBL5095170 ↗ |
| Route | Other | “intra-tumoral BMS-986299 monotherapy (part 1A)” PMID 39824531 ↗ Jan 2025 |